Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Obecabtagene autoleucel - Autolus

Next Previous
Drug Profile

Obecabtagene autoleucel - Autolus

Alternative Names: Anti-CD19 CAR T cell therapy - Autolus; AUCATZYL; AUTO 1; CAT19; CD19 CAR T-cells - Autolus; CD19CAT-41BBZ CAR T-cells - Autolus; Obe-cel

Latest Information Update: 09 Mar 2026

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator University College London
  • Developer Autolus; University College London
  • Class Antineoplastics; CAR-T cell therapies; Gene therapies; Immunotherapies
  • Mechanism of Action Immunologic cytotoxicity; T lymphocyte replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Precursor cell lymphoblastic leukaemia-lymphoma
  • New Molecular Entity No

Highest Development Phases

  • Marketed Precursor B-cell lymphoblastic leukaemia-lymphoma
  • Phase I/II Chronic lymphocytic leukaemia; Non-Hodgkin's lymphoma
  • Phase I Multiple sclerosis; Systemic lupus erythematosus

Most Recent Events

  • 06 Dec 2025 Efficacy, adverse event and pharmacokinetics data from a phase I trial in Precursor B-cell lymphoblastic leukaemia-lymphoma presented at the 67th American Society of Hematology Annual Meeting and Exposition (ASH-Hem-2025)
  • 06 Dec 2025 Efficacy data from a phase I/II trial in Precursor B-cell lymphoblastic leukaemia-lymphoma presented at the 67th American Society of Hematology Annual Meeting and Exposition (ASH-Hem-2025)
  • 06 Dec 2025 Efficacy, adverse events, pharmacodynamics and pharmacokinetics data from a phase-I CARLYSE trial in Systemic lupus erythematosus presented at the 67th American Society of Hematology Annual Meeting and Exposition (ASH-Hem-2025)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top